[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-stage3\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-stage3":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634810","feasibility-safety-and-efficacy-of-a-predominantly-plant-based-diet-in-an-asian-population-with-chronic-kidney-disease-100634810",false,"NCT07544524","Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease","Inclusion Criteria:\n\n1. Age 21-79 (Only adults who can give consent will be recruited. Older adults aged 80 are not included to reduce the risk of confounding due to age-related frailty, sarcopenia and multimorbidity. Additionally, older adults may have different nutritional needs and energy requirements)\n2. CKD stage 3-4 (baseline eGFR 15-60ml\u002Fmin\u002F1.72m2 for the past 6 months)\n3. Willingness to see a dietitian and follow either a standard CKD diet or a predominantly plant-based CKD diet\n4. On maximum tolerated dose of ACE-inhibitors (Angiotensin converting enzyme inhibitors) or ARB (Aldosterone receptor blocker) as determined by Renal Physician in charge\n5. Able to provide informed consent\n\nExclusion Criteria:\n\n* Transplant patients (who will tend to have more variable trajectories, immunosuppression related challenges etc which may make this study less feasible)\n* Pregnant or lactating patients (who have different nutritional requirements than the standard CKD patients)\n* Patients who were on any special diet for at least 1 month prior to recruitment (inclusive of\n* long-term vegans or vegetarians) - excluded because they already have stable dietary habits\n* Age \\\u003C21 or \\>\u002F= 80 (Avoid growing children who have different nutritional requirements and advanced elderly who are more likely to have malnutrition or sarcopenia due to other pre-existing causes)\n* Those who have seen a dietitian for CKD previously\n* Patients with severe ischemic heart disease, decompensated liver cirrhosis, malabsorptive diseases or malignancy\n* Patients with BMI \\\u003C18.5 or \\>40\n* Patients with glomerulonephritis, genetic kidney disease or polycystic kidney disease\n* Baseline serum potassium 5.0 and above\n* Patients who are unable to modify their diet due to socio-economic issues.\n* Exclude patients with acute kidney injury (AKI) in the past 6 months prior to study (unstable renal disease","ALL","21 Years","79 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital. Eligible patients with Stage 3 or 4 CKD will be assigned preferencebased to either a plant-based diet intervention (intake of at least 50% protein from plant sources) with regular dietitian counselling and follow up, or a control group receiving dietitian counselling for general CKD dietary advice without information on percentage of plant-based foods. Six monthly assessments will include estimated glomerular filtration rate (eGFR), serum potassium, nutritional markers, and other relevant biochemical parameters. Quality of life and dietary adherence will be evaluated through questionnaires and food frequency records. This study will evaluate primarily, the feasibility of a plant-based diet in the Singaporean context. Secondarily it will evaluate its safety in terms of incidence of hyperkalaemia, and benefit in terms of improvement in acidosis.\n\nOther exploratory outcomes will include (1) preliminary efficacy of plant-based diets on CKD progression (measured by eGFR decline); (2) risk of nutritional deficiencies such as vitamin D, B12 and iron; and (3) impact on other biochemical parameters of CKD.",[26,27,28],"Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","Diet Habit","RECRUITING","2026-04-15",{"date":32,"type":33},"2026-04-22","ACTUAL",{"date":35,"type":20},"2026-04-01",{"date":37,"type":20},"2027-09-30",{"name":39,"class":40},"Changi General Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":41},"100616706","clinical-morphometric-and-biochemical-effects-on-adiposopathy-associated-with-the-use-of-glp-1ra-in-ckd-100616706","NCT07309094","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease","ADIPO-CKD","Inclusion Criteria:\n\n* \\> or = 18 years of age\n* diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis\n* had uncontrolled T2DM, CVDs and\u002For obesity\n* willing to participate in the study and sign informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* pregnancy\n* CKD in stage G5 or G4 candidate for dialysis\n* neuropsychiatric diseases preventing the patient from understanding the benefits\u002Frisks associated with the project\n* refusal to participate and\u002For consent revocation were considered as exclusion criteria","18 Years","90 Years",{"count":53,"type":20},250,"OBSERVATIONAL","Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The accumulation of fat tissue around the organs in conditions of obesity or diabetes accelerates the production of pro-inflammatory factors that may worsen the kidney and heart damage. New antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), have proven beneficial effects on the kidney and heart due to several mechanisms, including anti-inflammatory actions and a potential action on the fat tissue.\n\nThe aim of this study is to assess the link between adiposopathy and CKD, by investigating the changes in adiposopathy measures throughout treatment with GLP-1RA to a sample of patients with CKD.",[26,27,57,58,59,60],"Chronic Kidney Disease Stage 1","Chronic Kidney Disease Stage 2","Obesity","Diabetes Mellitus, Type 2",[62,63,64,65,66,67,68],"chronic kidney disease","type 2 diabetes mellitus","GLP-1RA","adiposopathy","perivisceral adipose tissue","perirenal adipose tissue","inflammation","2025-12-15",{"date":71,"type":33},"2025-12-30",{"date":73,"type":33},"2023-09-15",{"date":75,"type":20},"2028-12-31",{"name":77,"class":40},"Cardenal Herrera University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":51,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100518122","evaluation-of-the-effectiveness-of-platelet-based-and-microvesicle-based-assays-to-predict-thrombotic-and-bleeding-risk-in-chronic-kidney-disease-patients-with-acute-coronary-syndrome-100518122","NCT06026436","Evaluation of the Effectiveness of Platelet-based and Microvesicle-based Assays to Predict Thrombotic and Bleeding Risk in Chronic Kidney Disease Patients With Acute Coronary Syndrome","INNOV CKD 1","Inclusion Criteria:\n\n* Man or woman ≥18 years old and \\\u003C90\n* If the subject is a woman, she must be on contraception or menopausal.\n* Non-ST-segment elevation ACS defined by the presence of at least 2 of the following criteria: (1) symptoms of myocardial ischemia, (2) electrocardiographic ST-segment abnormalities (depression or transient elevation of at least 0.1 mV) or T-wave inversion in at least in 2 contiguous leads, or (3) an elevated cardiac troponin value (above the upper limit of normal) 56 or ST segment elevation ACS scheduled for primary PCI defined 57 as a history of chest discomfort or ischemic symptoms of \\>20 minutes duration at rest ≤14 days prior to entry into the study with one of the following present on at least one ECG:\n\n  1. ST-segment elevation ≥1 mm in two or more contiguous ECG leads\n  2. New or presumably new left bundle branch block (LBBB).\n  3. ST-segment depression ≥1 mm in two anterior precordial leads (V1 through V4) with clinical history and evidence suggestive of true posterior infarction\n* Subject intended for an invasive strategy if NSTE-ACS or primary PCI if STE-ACS according to guidelines (appendix X)\n* Subject with CKD stage 3A or higher (estimated glomerular filtration rate (eGFR) ≤ 60 ml\u002Fmin\u002F1.73 m2 according to the CKD-EPI formula\n* Because of the documented biological variability of eGRF levels, patients with a eGRF \\\u003C 78 ml\u002Fmin\u002F1.73 m2 can be included in this study, based on previous blood test results and on the investigator's decision. The DFG level of 78 ml\u002Fmin\u002F1.73 m2 correspond to an increase of 30 % of a DFG of 60 ml\u002Fmin\u002F1.73 m2. Indeed, the literature estimated a DFG levels variability of 30 % 58-61.\n* Must be enrolled at a cardiac catheterization laboratory hospital or at a hospital\u002Fambulance service affiliated with a cardiac catheterization laboratory hospital.\n* Subject affiliated to or beneficiary of a social security system.\n* Subject having signed written informed consent.\n\nExclusion Criteria:\n\n* \\- Minors, pregnant or breast-feeding women;\n* Subject under chronic anticoagulant\n* Subject with thrombolytic therapy during the preceding 24 hours;\n* Subject with bleeding diathesis;\n* Subject not agreeing to participate.\n* Subject with contraindication to clopidogrel, ticagrelor or to another anti platelet agent.\n* Severe hepatic failure\n* Ischemic Stroke within one month or a history of hemorrhagic stroke\n* Platelet count\\\u003C100 000\n* Major surgery or trauma within 10 days\n* Life expectancy \\\u003C1 year\n* Known significant bleeding risk according to the physician judgment\n* Adults subject to a legal protection measure or unable to express their consent (persons under guardianship, curatorship or safeguard of justice)\n* Persons deprived of their rights of liberty by judicial or administrative decision (persons in a situation of social fragility)\n* Progressive cancer\n* Systemic autoimmune disease\n* Chronic viral or bacterial infections\n* Diabetes requiring insulin therapy\n* Constitutional haemorrhagic syndrome\n* Organ transplantation",{"count":86,"type":20},850,[23],"This study is part of the RHU INNOV-CKD, winner of the 2019 call for projects. Its aim is to develop two biomarker assays to assess the thrombotic and haemorrhagic risks in patients with stage 3A or more severe chronic kidney disease (CKD) treated with percutaneous coronary intervention (PCI) and antiplatelet therapy following an acute coronary syndrome (ACS). We believe that these tests will help to adapt antiplatelet therapy on an individual basis (in terms of intensity and duration of treatment) and thus reduce the risk of thrombotic and haemorrhagic events in this particularly fragile population. The first biomarker corresponds to an intra-platelet molecule, Rap1b in its active form (known as aRap1b). The second is the pro-antithrombotic balance of circulating endothelial microvesicles (patEMV), which reflects endothelial dysfunction. An automated method for measuring these biomarkers will be developed in partnership with the D.Stago and BioCytex industries during the course of the project.",[26],"2023-10-26",{"date":92,"type":33},"2023-10-27",{"date":94,"type":33},"2023-10-12",{"date":96,"type":20},"2026-12",{"name":98,"class":40},"Assistance Publique Hopitaux De Marseille"]